MedTrace Logo

Evaluation of Tolerance and Efficacy Retrospective Data of XOFIGO

NCT04516707 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2020-08-18

No results posted yet for this study

Summary

Since 13 November 2013, XOFIGO has been authorised on the European zone for the treatment of patients with prostate cancer, in the phase of resistance to castration, with symptomatic bone metastases.

bone metastases frequently give rise to "bone events" that include spinal cord compressions and pathological fractures requiring surgery or external radiotherapy.

Bone metastases are an important cause of death, disability, quality of life degradation and increase the cost of treatment.

Xofigo is indicated in patients with bone metastases symptomatic of hormone-resistant prostate cancer and without known visceral metastases.

Conditions

Interventions

OTHER

clinical database

The various clinicam database will be collected solely to meet the objectives of the study. All data collected to create the database for this project will be anonymized

Sponsors & Collaborators

  • Institut du Cancer de Montpellier - Val d'Aurelle

    lead OTHER

Principal Investigators

  • Emmanuel DESHAYES, MD · ICM Val d'Aurelle

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2017-01-01
Completion
2018-05-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04516707 on ClinicalTrials.gov